NCT04939701: Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ESO
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have tumors that are NY-ESO-1+; Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients who have received prior checkpoint inhibitor therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with active untreated brain metastasis or leptomeningeal disease – see trial for details

Comments are closed.

Up ↑